Cannabinoids

After its public listing last October, shares in Canbud appear poised to move higher as it executes on its three-pronged business model: 1) Hemp for cannabinoids (CBD) production, (2) Mushrooms for both psychedelic pharmaceuticals and non-psychedelic nutraceuticals, and (3) Plant-based products. [more]